Arbutus Biopharma Corp. buy Maxi_Scalibusa
Start price
16.11.20
/
50%
€3.45
Target price
16.11.21
-
Performance (%)
-14.81%
End price
17.11.21
€2.94
Summary
This prediction ended on 17.11.21 with a price of €2.94. The price of Arbutus Biopharma Corp. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -14.81%. Maxi_Scalibusa has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Arbutus Biopharma Corp. | -0.578% | -0.578% | 2.953% | 7.285% |
| iShares Core DAX® | -1.785% | -1.250% | 11.664% | 12.714% |
| iShares Nasdaq 100 | -2.154% | 0.300% | 37.531% | 41.653% |
| iShares Nikkei 225® | -4.028% | -3.746% | 17.142% | 0.393% |
| iShares S&P 500 | -1.969% | 0.307% | 25.617% | 40.084% |
According to Maxi_Scalibusa what are the pros and cons of Arbutus Biopharma Corp. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Stable Large shareholder and/or long term investor
Future proof or reliable business model
Cons
Comments by Maxi_Scalibusa for this prediction
In the thread Arbutus Biopharma Corp. diskutieren
Buy Arbutus Biopharma Corp.
In the thread Trading Arbutus Biopharma Corp.
Die von Maxi_Scalibusa gewählte maximale Laufzeit wurde überschritten
Stopped prediction by Maxi_Scalibusa for Arbutus Biopharma Corp.
Arbutus Biopharma Corp.
Start price
Target price
Perf. (%)
€4.85
01.12.21
01.12.21
-
01.12.22
01.12.22
-53.67%
02.12.22
02.12.22
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Stable Large shareholder and/or long term investor
Future proof or reliable business model
